FDA Approves New Dosing Schedule for Lilly's Alzheimer's Drug Kisunla
FDA Approves New Dosing Schedule for Lilly's Alzheimer's Drug Kisunla

FDA Approves New Dosing Schedule for Lilly's Alzheimer's Drug Kisunla

News summary

The U.S. Food and Drug Administration (FDA) has approved a new, more gradual titration dosing schedule for Eli Lilly's Kisunla (donanemab-azbt), a once-monthly amyloid-targeting therapy for early symptomatic Alzheimer's disease. This updated regimen, supported by the TRAILBLAZER-ALZ 6 study, significantly reduces the incidence of amyloid-related imaging abnormalities with edema/effusion (ARIA-E), a potentially serious side effect involving brain swelling, by 35-41% compared to the original dosing schedule. The new dosing shifts the initial doses to start with one vial and gradually increases to the full dose by month four, maintaining the same overall amount of drug by week 24 without compromising its efficacy in amyloid plaque removal or slowing cognitive decline. Kisunla's improved safety profile with fewer and less severe ARIA-E events enhances its benefit-risk balance and is expected to aid healthcare professionals in treatment decisions. Despite its efficacy, adoption of Kisunla and similar drugs remains slow due to the need for extra diagnostic tests and monitoring for side effects. The label update reflects Lilly's commitment to patient safety and advancing Alzheimer's treatment options.

Story Coverage
Bias Distribution
100% Center
Information Sources
a3544a73-dab3-486d-ae75-bd4d15f01f55
Center 100%
Coverage Details
Total News Sources
1
Left
0
Center
1
Right
0
Unrated
0
Last Updated
13 hours ago
Bias Distribution
100% Center
Related News
Daily Index

Negative

26Serious

Neutral

Optimistic

Positive

Ask VT AI
Story Coverage

Related Topics

Subscribe

Stay in the know

Get the latest news, exclusive insights, and curated content delivered straight to your inbox.

Present

Gift Subscriptions

The perfect gift for understanding
news from all angles.

Related News
Recommended News